BR0210489A - Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente - Google Patents

Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente

Info

Publication number
BR0210489A
BR0210489A BR0210489-0A BR0210489A BR0210489A BR 0210489 A BR0210489 A BR 0210489A BR 0210489 A BR0210489 A BR 0210489A BR 0210489 A BR0210489 A BR 0210489A
Authority
BR
Brazil
Prior art keywords
preparing
oral pharmaceutical
formulation
patient
pharmaceutical formulation
Prior art date
Application number
BR0210489-0A
Other languages
English (en)
Inventor
Cynthia Gaik-Lim Khoo
Helena Gustafsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0210489A publication Critical patent/BR0210489A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

"FORMULAçãO FARMACêUTICA ORAL, PROCESSO PARA PREPARAR A MESMA, USO DA MESMA, E MéTODO PARA PREPARAR UM DISTúRBIO CARDIOVASCULAR EM UM PACIENTE". Uma formulação farmacêutica oral compreendendo iota-carragenano, um ou mais polímeros neutros geleificantes e um ingrediente farmaceuticamente ativo básico; sendo que referida formulação inibe a liberação do ingrediente farmaceuticamente ativo básico da formulação a pH ácido; um processo para a fabricação de referida formulação; e o uso de referida formulação na medicina.
BR0210489-0A 2001-06-21 2002-06-19 Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente BR0210489A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation
PCT/SE2002/001217 WO2003000293A1 (en) 2001-06-21 2002-06-19 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BR0210489A true BR0210489A (pt) 2004-06-22

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210489-0A BR0210489A (pt) 2001-06-21 2002-06-19 Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente

Country Status (31)

Country Link
US (1) US7700582B2 (pt)
EP (1) EP1401502B1 (pt)
JP (1) JP2005501024A (pt)
KR (1) KR20040011542A (pt)
CN (1) CN1518462A (pt)
AR (1) AR034517A1 (pt)
AT (1) ATE314093T1 (pt)
AU (1) AU2002345463B2 (pt)
BG (1) BG108516A (pt)
BR (1) BR0210489A (pt)
CA (1) CA2450449A1 (pt)
CO (1) CO5550466A2 (pt)
CZ (1) CZ299859B6 (pt)
DE (1) DE60208369T2 (pt)
DK (1) DK1401502T3 (pt)
EE (1) EE200400028A (pt)
ES (1) ES2254699T3 (pt)
HU (1) HUP0400850A3 (pt)
IL (2) IL159217A0 (pt)
IS (1) IS2347B (pt)
MX (1) MXPA03011546A (pt)
MY (1) MY130332A (pt)
NO (1) NO20035627D0 (pt)
NZ (1) NZ530086A (pt)
PL (1) PL366432A1 (pt)
RU (1) RU2323006C2 (pt)
SI (1) SI1401502T1 (pt)
SK (1) SK286238B6 (pt)
UA (1) UA77959C2 (pt)
WO (1) WO2003000293A1 (pt)
ZA (1) ZA200309316B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
PL374280A1 (en) * 2001-11-13 2005-10-03 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006046954A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
DE602008003522D1 (de) * 2007-02-01 2010-12-30 Takeda Pharmaceutical Feste zubereitung mit alogliptin und pioglitazon
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
EA018638B1 (ru) 2008-08-01 2013-09-30 Крка, Товарна Здравил, Д. Д., Ново Место Композиция кветиапина
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (pt) * 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
DE69314478T2 (de) 1992-03-04 1999-02-11 Gyogyszerkutato Intezet Neuartige antikoagulierende peptidderivate und arzneimittel die solche enthalten so wie entsprechendes herstellungsverfahren
TW223629B (pt) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301912D0 (sv) * 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
AU708001B2 (en) * 1995-02-17 1999-07-29 Abbott Gmbh & Co. Kg Novel thrombin inhibitors
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
JP2000514788A (ja) 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
DE69936212T2 (de) * 1998-09-04 2008-01-24 Scios Inc., Sunnyvale Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
CA2355792A1 (en) * 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
SK286238B6 (sk) 2008-06-06
US7700582B2 (en) 2010-04-20
HUP0400850A2 (hu) 2004-08-30
DE60208369D1 (de) 2006-02-02
NO20035627D0 (no) 2003-12-15
SI1401502T1 (sl) 2006-06-30
ZA200309316B (en) 2005-02-28
WO2003000293A1 (en) 2003-01-03
DE60208369T2 (de) 2006-08-24
CA2450449A1 (en) 2003-01-03
EP1401502B1 (en) 2005-12-28
US20040242536A1 (en) 2004-12-02
RU2323006C2 (ru) 2008-04-27
BG108516A (en) 2004-12-30
CO5550466A2 (es) 2005-08-31
IS7081A (is) 2003-12-16
NZ530086A (en) 2005-09-30
JP2005501024A (ja) 2005-01-13
AR034517A1 (es) 2004-02-25
ES2254699T3 (es) 2006-06-16
HUP0400850A3 (en) 2010-10-28
IS2347B (is) 2008-03-15
MXPA03011546A (es) 2004-03-19
DK1401502T3 (da) 2006-04-10
IL159217A (en) 2009-02-11
ATE314093T1 (de) 2006-01-15
EP1401502A1 (en) 2004-03-31
CN1518462A (zh) 2004-08-04
MY130332A (en) 2007-06-29
RU2003136155A (ru) 2005-05-20
SK15912003A3 (sk) 2004-05-04
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
CZ20033491A3 (en) 2004-03-17
AU2002345463B2 (en) 2007-08-30
IL159217A0 (en) 2004-06-01
CZ299859B6 (cs) 2008-12-17
EE200400028A (et) 2004-04-15
UA77959C2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
NO20014724D0 (no) Pregelatinisert stivelse i en formulering med regulert frigivning
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
UY25544A1 (es) Forma de dosificación de nefazodona
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
HK1068606A1 (en) Novel aminobenzoephenones
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
BRPI0414305A (pt) sistema de liberação de drogas por via oral
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
AR036877A1 (es) Formulacion farmaceutica
SE0001916D0 (sv) Novel formulation
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
SE0102887D0 (sv) New formulation
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
DE50005714D1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
UY27345A1 (es) Formulación farmacéutica.
BR0008241A (pt) Utilização de fanquinona para a preparação deuma composição farmacêutica para o tratamentode enfraquecimento de memória e método detratamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.